scispace - formally typeset
H

Håvard Jenssen

Researcher at Roskilde University

Publications -  106
Citations -  7940

Håvard Jenssen is an academic researcher from Roskilde University. The author has contributed to research in topics: Antimicrobial peptides & Antimicrobial. The author has an hindex of 39, co-authored 96 publications receiving 6676 citations. Previous affiliations of Håvard Jenssen include University Hospital of North Norway & University of Tromsø.

Papers
More filters
Journal ArticleDOI

Peptide Antimicrobial Agents

TL;DR: The structural requirements of peptides for antiviral and antibacterial activities are evaluated in light of the diverse set of primary and secondary structures described for host defense peptides.
Journal ArticleDOI

Antimicrobial properties of lactoferrin

TL;DR: This review focuses on the antimicrobial activities of lactoferrin with particular emphasis on antibacterial and antiviral activities, although its antifungal and -parasitic activity are also discussed.
Journal ArticleDOI

Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant Superbugs

TL;DR: The best peptides, representing the top quartile of predicted activities, were effective against a broad array of multidrug-resistant "Superbugs" with activities that were equal to or better than four highly used conventional antibiotics.
Journal ArticleDOI

Antimicrobial peptides on calcium phosphate-coated titanium for the prevention of implant-associated infections.

TL;DR: It was demonstrated that CaP-Tet213 was a more efficient antimicrobial coating following incubation of CaP implants with equimolar concentrations of Tet213, the commercially developed antimicrobial peptide MX-226, hLF1-11 or tobramycin.
Journal ArticleDOI

Identification of novel antibacterial peptides by chemoinformatics and machine learning.

TL;DR: The best peptides identified through screening were found to have activities comparable or superior to those of four conventional antibiotics and superior to the peptide most advanced in clinical development against a broad array of multiresistant human pathogens.